Cheshire, UK -- (MARKET WIRE) -- March 19, 2007 --
Protherics PLC
Notification of Major Interests in Shares
London, UK; Brentwood, TN, US: 19 March 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that, on 16 March 2007, a notification of interest in
the ordinary share capital of the Company was received from AXA Investment
Managers Limited on behalf of AXA S.A. in accordance with the Transparency
Obligations Directive. Details of the interest notified are as follows:
1. Reason for the notification (please tick the appropriate box or boxes)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify): CONFIRMATION OF CURRENT POSITION USING STANDARD FORM AS x
REQUIRED BY EUTD REGULATIONS
2. Full name of person(s) subject to the AXA S.A., 25 Avenue Matignon,
notification obligation: 75008 Paris and its group of
companies.
3. Full name of shareholder(s) (if different
from 2.):
4. Date of the transaction (and date on which 2 March 2007
the threshold is crossed or reached if
different):
5. Date on which issuer notified: 16 March 2007
6. Threshold(s) that is/are crossed or reached:
7. Notified details:
A: Voting rights attached to shares
Class/type of Situation previous to Resulting situation after the triggering transaction
shares the Triggering
transaction
if possible using Number of Number of Number of Number of voting rights % of voting rights
the ISIN CODE Shares Voting shares
Rights Direct Direct Indirect Direct Indirect
GB0007029209 318,221 318,221 33,039,187 0.09% 9.74%
B: Financial Instruments
Resulting situation after the triggering transaction
Type of financial Expiration date Exercise/ Conversion Number of voting rights % of voting rights
instrument Period/ Date that may be acquired if
the instrument is
exercised/ converted.
Total (A+B)
Number of voting rights % of voting rights
33,357,408 9.84%
8. Chain of controlled undertakings through which the voting rights and/or the financial instruments are
effectively held, if applicable :
Name of Company/Fund Number of Shares % of issued share capital
AXA UK Investment Co ICVC 1,113,331 0.32831
UK Smaller Companies Fund
Indirect
Sun Life Pensions Management Ltd 11,250 0.00332
Direct
Sun Life Unit Assurance Ltd 53,913 0.01590
FTSE All Share Tracker
Direct
Sun Life Pensions Management 253,058 0.07462
FTSE All Share Tracker
Direct
AXA Framlington 13,434,482 3.96170
UK Select Ops
Indirect
AXA Framlington 13,753,131 4.05567
Equity Income
Indirect
AXA Framlington 1,329,998 0.39220
Health
Indirect
AXA Framlington 900,000 0.26540
Managed Balanced
Indirect
AXA Framlington 592,599 0.17475
Biotech
Indirect
AXA Framlington 394,259 0.11626
BAE Systems Pensions Fund CIF Trustees
Indirect
AXA Framlington 176,049 0.05192
BAE Systems 2000 Pensions Fund
Indirect
Framlington onshore private clients 1,289,088 0.38014
Indirect
Framlington onshor private clients 56,250 0.01659
Indirect
Total Direct 318,221 0.09384
Total Indirect 33,039,187 9.74295
TOTAL 33,357,408 9.83679
Proxy Voting:
9. Name of the proxy holder:
10. Number of voting rights proxy holder will cease to hold:
11. Date on which proxy holder will cease to hold voting
rights:
12. Additional information:
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange